A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
Breast cancer (BC) is the most commonly diagnosed cancer globally, with high mortality rates. Targeted drug therapies have revolutionized cancer treatment. For example, treatment with human epidermal receptor 2 (HER2) antagonists has markedly improved the prognosis of patients with HER2-positive BC...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/1/38 |
| _version_ | 1797626203480260608 |
|---|---|
| author | Moudi M. Alasmari |
| author_facet | Moudi M. Alasmari |
| author_sort | Moudi M. Alasmari |
| collection | DOAJ |
| description | Breast cancer (BC) is the most commonly diagnosed cancer globally, with high mortality rates. Targeted drug therapies have revolutionized cancer treatment. For example, treatment with human epidermal receptor 2 (HER2) antagonists has markedly improved the prognosis of patients with HER2-positive BC (HER2 + BC). However, HER2+ metastatic BC (MBC) remains prevalent owing to its resistance to conventional anti-HER2 drugs. Therefore, novel agents are needed to overcome the limitations of existing cancer treatments and to enhance the progression-free and overall survival rates. Progress has been made by optimizing the fragment crystallizable (Fc) domain of trastuzumab, an IgG1 monoclonal, chimeric anti-HER2 antibody, to develop margetuximab. The modified Fc domain of margetuximab enhances its binding affinity to CD16A and decreases its binding affinity to CD32B, thereby promoting its antitumor activity. This review summarizes studies on the efficacy of margetuximab, discusses its utility as an anti-HER2 monoclonal antibody drug for the treatment of HER2 + BC, and presents the latest advances in the treatment of BC. This review provides insights into the clinical implication of margetuximab in HER2 + MBC treatment. |
| first_indexed | 2024-03-11T10:07:07Z |
| format | Article |
| id | doaj.art-b30c4f0e91984ef39bb6b60d318187ac |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T10:07:07Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b30c4f0e91984ef39bb6b60d318187ac2023-11-16T15:00:46ZengMDPI AGCancers2072-66942022-12-011513810.3390/cancers15010038A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast CancerMoudi M. Alasmari0College of Medicine, King Saud Bin Abdul Aziz University for Health Sciences (KSAU-HS), Jeddah 21461, Saudi ArabiaBreast cancer (BC) is the most commonly diagnosed cancer globally, with high mortality rates. Targeted drug therapies have revolutionized cancer treatment. For example, treatment with human epidermal receptor 2 (HER2) antagonists has markedly improved the prognosis of patients with HER2-positive BC (HER2 + BC). However, HER2+ metastatic BC (MBC) remains prevalent owing to its resistance to conventional anti-HER2 drugs. Therefore, novel agents are needed to overcome the limitations of existing cancer treatments and to enhance the progression-free and overall survival rates. Progress has been made by optimizing the fragment crystallizable (Fc) domain of trastuzumab, an IgG1 monoclonal, chimeric anti-HER2 antibody, to develop margetuximab. The modified Fc domain of margetuximab enhances its binding affinity to CD16A and decreases its binding affinity to CD32B, thereby promoting its antitumor activity. This review summarizes studies on the efficacy of margetuximab, discusses its utility as an anti-HER2 monoclonal antibody drug for the treatment of HER2 + BC, and presents the latest advances in the treatment of BC. This review provides insights into the clinical implication of margetuximab in HER2 + MBC treatment.https://www.mdpi.com/2072-6694/15/1/38margetuximabFc engineeringclinical trialsanti-HER2 therapyhuman epidermal receptor 2positive metastatic breast cancer |
| spellingShingle | Moudi M. Alasmari A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer Cancers margetuximab Fc engineering clinical trials anti-HER2 therapy human epidermal receptor 2 positive metastatic breast cancer |
| title | A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer |
| title_full | A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer |
| title_fullStr | A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer |
| title_full_unstemmed | A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer |
| title_short | A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer |
| title_sort | review of margetuximab based therapies in patients with her2 positive metastatic breast cancer |
| topic | margetuximab Fc engineering clinical trials anti-HER2 therapy human epidermal receptor 2 positive metastatic breast cancer |
| url | https://www.mdpi.com/2072-6694/15/1/38 |
| work_keys_str_mv | AT moudimalasmari areviewofmargetuximabbasedtherapiesinpatientswithher2positivemetastaticbreastcancer AT moudimalasmari reviewofmargetuximabbasedtherapiesinpatientswithher2positivemetastaticbreastcancer |